At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 12, 2026 at 16:01 ET
Erasca reported a Q3 2026 net loss of $51.3M ($0.15/share), wider than the $30.6M loss a year ago, driven by increased R&D spending. The company highlighted FDA Fast Track Designation for ERAS-0015 in pancreatic cancer and a strong cash position of $948M following a $632.5M public offering, funding key milestones through 2027-2028.
- Net loss of $51.3M ($0.15/share) for Q3 2026 vs $30.6M ($0.11/share) in Q3 2025
- Cash, cash equivalents, and marketable securities of $947.8M as of Sep 30, 2026, up from $341.8M at Dec 31, 2025
- Completed upsized public offering in July 2026 raising ~$632.5M in gross proceeds
- FDA Fast Track Designation granted to ERAS-0015 for metastatic pancreatic adenocarcinoma in August 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access